Nanoparticles enhance drug solubility, stability, and bioavailability, improving therapeutic outcomes for GI conditions like IBD through targeted delivery mechanisms. Hydrogel-based systems offer ...
AbbVie is securing its place in an emerging gastrointestinal disease drug field, paying China-based FutureGen Biopharmaceutical $150 million in immediate and near-term fees for rights to an antibody ...
Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical activity. (Photo by: Michael ...
Ironwood Pharmaceuticals, a company whose drug research yielded a blockbuster gastrointestinal disorder drug, has struck a $1 billion deal to acquire VectivBio, a biotech whose lead program brings ...
GLP-1 medications such as Ozempic and Wegovy, commonly prescribed for weight loss, may also benefit cognitive and behavioral health. However, this popular class of drugs, which also includes Mounjaro ...
Researchers have developed a human intestinal cell model that closely mimics the structure and function of the human gut, enabling more precise prediction of drug-induced gastrointestinal toxicity ...
Among the most recently approved drugs for weight management, glucagon-like peptide 1 (GLP-1) agonists have garnered considerable attention; however, the effects of these drugs on the gastrointestinal ...
When used as a weight-loss tool, the glucagon-like peptide-1 (GLP-1) receptor agonists semaglutide (Ozempic) and liraglutide (Saxenda), both sold by Novo Nordisk, raise the odds that patients will ...
Inspired by the jets of water that squids use to propel themselves through the ocean, a team developed an ingestible capsule that releases a burst of drugs directly into the lining of the stomach or ...
Lawsuits filed against the manufacturers of Ozempic, Mounjaro, and other weight control and diabetes drugs have alleged that these medications can cause serious gastrointestinal side effects, ...
NEW YORK (Reuters Health) - Although all of the common strategies protect the upper gastrointestinal tract from the complications of nonsteroidal anti-inflammatory drugs (NSAIDs), popular ...
Please provide your email address to receive an email when new articles are posted on . Gastroenterology had a big year in 2022, with potentially game-changing FDA approvals for inflammatory bowel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results